Literature DB >> 8099862

Importance of early blood sampling on vecuronium pharmacokinetic and pharmacodynamic parameters.

J Ducharme1, F Varin, D R Bevan, F Donati.   

Abstract

The effect of early blood sampling on the description of the vecuronium pharmacokinetic-pharmacodynamic relationship was studied following a bolus injection. Sample collection every 10 sec during the first 2 min showed a high concentration peak at 30 to 40 sec, accounting for an important proportion of the total area under the plasma concentration-time curve (AUC). Neglecting it, using only blood samples drawn at 1 and 2 min (limited sampling), led to a significant overestimation of noncompartmentally derived values of mean residence time, clearance, volume of distribution at steady-state and rate of transfer of vecuronium into the effect compartment. Compartmental pharmacokinetics could not be applied to concentration-time curves constructed with early samples, but limited sampling data were fitted to a 2-compartment model. Derived compartmental pharmacokinetic and pharmacokinetic-pharmacodynamic parameters were similar to those obtained noncompartmentally with complete sampling every 10 sec, because back-extrapolation to time zero contributed to the increase in the AUC. However, compartmental analysis does not provide an accurate description of concentration changes following injection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099862     DOI: 10.2165/00003088-199324060-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  31 in total

1.  A comparison of parametric with semiparametric analysis of the concentration versus effect relationship of metocurine in dogs and pigs.

Authors:  S L Shafer; J R Varvel; G A Gronert
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

2.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

Review 3.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

4.  Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure.

Authors:  A F Bencini; A H Scaf; Y J Sohn; C Meistelman; A Lienhart; U W Kersten; S Schwarz; S Agoston
Journal:  Anesth Analg       Date:  1986-03       Impact factor: 5.108

5.  Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure.

Authors:  M R Fahey; R B Morris; R D Miller; T L Nguyen; R A Upton
Journal:  Br J Anaesth       Date:  1981-10       Impact factor: 9.166

6.  Fast events in single-channel currents activated by acetylcholine and its analogues at the frog muscle end-plate.

Authors:  D Colquhoun; B Sakmann
Journal:  J Physiol       Date:  1985-12       Impact factor: 5.182

7.  Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia.

Authors:  C A Shanks; M J Avram; R J Fragen; D A O'Hara
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

Review 8.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

9.  Pharmacokinetics and pharmacodynamics of Org NC 45 in man.

Authors:  F van der Veen; A Bencini
Journal:  Br J Anaesth       Date:  1980       Impact factor: 9.166

10.  Pharmacology of vecuronium in patients with end-stage renal failure.

Authors:  C Meistelman; A Lienhart; C Leveque; M O Bitker; B Pigot; P Viars
Journal:  Eur J Anaesthesiol       Date:  1986-03       Impact factor: 4.330

View more
  7 in total

1.  Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?

Authors:  T M Beaufort; J H Proost; K Kuizenga; M C Houwertjes; U W Kleef; J M Wierda
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

2.  An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs.

Authors:  J H Proost; J M Wierda; D K Meijer
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

3.  Determination of the distribution volume that can be used to calculate the intravenous loading dose.

Authors:  D R Wada; D R Drover; H J Lemmens
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

4.  Pharmacokinetic-pharmacodynamic modeling of doxacurium: effect of input rate.

Authors:  Y Zhu; G Audibert; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

Review 5.  Clinical pharmacokinetics of cisatracurium besilate.

Authors:  D F Kisor; V D Schmith
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

6.  Simulation of the kinetics of neuromuscular block: implications for speed of onset.

Authors:  James P Dilger
Journal:  Anesth Analg       Date:  2013-03-01       Impact factor: 5.108

7.  Neuromuscular effects of vecuronium and neostigmine in Montreal and Paris.

Authors:  Y Salib; J Frossard; B Plaud; B Debaene; C Meistelman; F Donati
Journal:  Can J Anaesth       Date:  1994-10       Impact factor: 5.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.